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Abstract:  Posaconazole  is  an  extended-spectrum  azole  antifungal  that  exhibits  activity 
against a broad range of fungal pathogens, including yeasts and moulds. Clinical data have 
demonstrated the clinical utility of posaconazole against many therapy-refractory pathogens, 
including Aspergillus spp, Fusarium spp, and Zygomycetes. These data have provided clinicians 
with hope in these difficult situations. Some of the limitations that have emerged with the use 
of posaconazole are the lack of an intravenous formulation and erratic drug absorption. This 
fact is further complicated by the existence of saturable posaconazole absorption. Despite 
these drawbacks, posaconazole appears poised to become a prominent therapeutic modality for 
the prophylaxis and management of various fungal infections among high-risk patients.
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Introduction
In recent years, the incidence of invasive fungal infections has increased dramatically. 
While this can be contributed to multiple factors, advances in medical technology 
appear to have had the most dramatic effect.1,2 Although medical breakthroughs have 
improved the survival of patients with a variety of life-threatening illnesses, these 
same advances have simultaneously created populations at increased risk for acquiring 
invasive fungal infections.2,3 Examples of these extremely susceptible patient groups 
include human immunodeficiency virus (HIV)-infected individuals, solid organ and 
hematopoietic stem cell transplant recipients, oncology patients, thermal injury patients, 
individuals with indwelling medical devices, and low-birth-weight infants.2
Historically, Candida and Aspergillus were the two most prominent fungal   species 
to cause human infections. Although Candida species are still the fourth most   common 
cause of nosocomial blood stream infections, various other moulds and yeasts are 
becoming increasingly more common.2,4,5 Infection from previously rarely encountered 
organisms, such as Blastomyces dermatitidis, Coccidioides species, Fusarium species, 
Histoplasma capsulatum, and Zygomycetes are now more commonly encountered.4 
Along with the emergence of infections caused by a broader array of fungal pathogens, 
increasing rates of drug resistance among Candida and Aspergillus spp to commonly 
used antifungal agents have been reported.3,5 These factors have complicated the 
management of fungal infections and have challenged clinicians to rethink empiric 
choices.1,3,5,6
For decades, amphotericin B had been considered the gold-standard   antifungal for 
treatment of serious fungal infections.4 The broad spectrum of activity of   amphotericin B 
has made it attractive for empiric therapy; however, associated toxicities have greatly Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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limited its use.1,4 The safety and tolerability of antifungal 
treatments improved significantly with the approval of the 
“first-generation” azoles, fluconazole and itraconazole.1,5 
Fluconazole provided clinicians with a safe and effective 
alternative to amphotericin B. However, lack of activity 
against moulds, including Aspergillus species, and concerns 
over the emergence of fluconazole-resistant Candida 
species negatively impacted the use of flucaonazole.1,3–5 
Although itraconazole exhibits superior activity against some 
moulds compared with fluconazole, it still has poor activity 
against many emerging pathogens, such as Fusarium spp, 
  Zygomycetes, and some Scedosporium spp.4 Furthermore, 
erratic absorption and delayed availability of an intravenous 
formulation contributed to the negative stigma associated with 
itraconazole. The development of the “second-generation” 
triazoles, voriconazole and posaconazole, ushered in a new 
group of antifungal agents with enhanced spectrum of activity 
against moulds, including Aspergillus spp, Fusarium spp, and 
Scedosporium spp.1,5 Additionally, posaconazole possesses 
activity against some Zygomycetes.4 Owing to their broad 
spectrum of activity against emerging moulds and some 
fluconazole-resistant strains, clinical interest in these two 
agents has been substantial.1,5
This paper reviews the pharmacokinetic and   clinical 
data for posaconazole. Other information needed to 
allow the clinician to make informed treatment decisions, 
including safety, tolerability, and quality of life data are also 
presented.
Mechanism of action
Posaconazole is an extended-spectrum triazole antifungal 
available for oral administration.7 Posaconazole exerts its activ-
ity by binding to and inhibiting lanosterol-14 α-demethylase. 
As a result, the conversion of lanosterol to ergosterol is inter-
rupted at one of the last steps of the biosynthesis pathway. 
Lanosterol-14 α-demethylase is a member of the cytochrome 
P450 (CYP450) enzyme family, and is found in nearly all 
types of fungi. Ergosterol is responsible for helping main-
tain the cellular membrane activity and integrity of fungi, 
and is not found in human cellular membranes, making its 
production an excellent target for antifungal therapy.7,8 Inter-
ference in the production of ergosterol disrupts the cellular 
membrane activity of fungi. However, because the interac-
tion of posaconazole with CYP450 enzymes is not limited 
to lanosterol-14 α-demethylase, posaconazole does have the 
potential to interfere with hepatic isoenzymes responsible 
for drug metabolism.
It is interesting to note that the chemical structure of 
posaconazole is larger than that of the other azoles. This 
characteristic is theorized to allow posaconazole to attach 
to multiple binding domains on the target enzyme and offer 
a lower affinity to drug efflux pumps.8–10
Pharmacokinetics
Absorption
Posaconazole is currently available as a suspension for oral 
administration. This formulation was developed as a result 
of the finding that an oral suspension provided greater 
  bioavailability than a tablet formulation.11 Despite the better 
bioavailability of the posaconazole suspension, absorption is 
still quite erratic. In a study of 56 healthy volunteers receiv-
ing a 400 mg dose of the oral suspension, the   steady-state 
area under the concentration-time curve (AUC) among 
subjects ranged from roughly 14,000 to 70,000 ng•h/mL.12 
Furthermore, the coefficients of variation noted for AUCs 
and peak concentrations were roughly 40%.12 These 
observations highlight the tremendous variability associated 
with the absorption of posaconazole, even under the best of 
conditions. Several studies have attempted to determine the 
factors responsible for the enormous interpatient variability 
associated with the absorption of posaconazole. Subsequently, 
it was reported that low gastric pH and coadministration of 
the dose with a high-fat meal may increase posaconazole 
absorption by up to 400%.13 In contrast, higher gastric pH 
and presence of diarrhea can decrease the absorption of posa-
conazole by up to 60%.13,14 Additionally, underlying patient 
factors, such as bone marrow transplantation and mucositis, 
can also greatly contribute to inter- and intrapatient variability 
with respect to drug absorption.15,16
Another compounding element that has complicated 
attainment of predictable drug levels among patients was 
the identification of saturable absorption of posaconazole 
following oral administration.17 In a group of healthy adults, 
it was observed that plasma concentrations of posaconazole 
were maximized at doses of 800 mg.17 Similarly, in 
various patient populations, overall systemic exposure to 
posaconazole was found to plateau at doses of 200 mg to 
400 mg.15,16 In one study, 98 patients with proven or possible 
fungal disease were randomized to receive one of three posa-
conazole regimens, ie, 200 mg four times daily for nine doses 
followed by 400 mg twice daily, 400 mg four times daily for 
nine doses followed by 600 mg twice daily, or 800 mg twice 
daily for five doses followed by 800 mg once daily.16 Mean 
steady-state peak concentrations were 581 ng/mL, 579 ng/mL, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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and 361 ng/mL for posaconazole dosed 400 mg twice daily, 
600 mg twice daily, and 800 mg once daily, respectively. 
Likewise AUC0-τ was 8619 ng•h/mL, 5823 ng•h/mL, and 
6199 ng•h/mL for posaconazole dosed 400 mg twice daily, 
600 mg twice daily, and 800 mg once daily, respectively. 
It was noted that the 400 mg twice daily dose provided a 135% 
higher mean exposure than the 600 mg twice daily dose, and 
a 182% higher mean exposure than the 800 mg once daily 
dose (P = 0.0004, P , 0.0001, respectively). The authors of 
this study concluded that despite the long half-life of posacon-
azole, a dosing regimen of 400 mg twice daily provided the 
highest overall systemic exposure to posaconazole. It has been 
hypothesized that a concentration-dependent first-pass effect 
and/or the poor solubility of posaconazole may contribute to 
this apparent saturable absorption.
Distribution
Posaconazole distributes extensively throughout the body. 
It has a reported volume of distribution of around 1774 L 
and is extensively bound to albumin (98%).7 The volume of 
distribution has been reported to be somewhat less in older 
adults.12 This difference in volume of distribution may result 
in slightly greater exposure to posaconazole among older 
adults. However, owing to the large interpatient variability 
with respect to absorption, this observation is not likely to 
be clinically significant.
Interestingly, studies conducted in healthy and lung 
transplant recipients revealed that posaconazole achieves 
high levels in alveolar cells.18,19 In fact, the authors reported 
alveolar cell to peak plasma posaconazole ratios of 33:1 in 
healthy subjects and 55:1 in lung transplant recipients.18,19
Metabolism
Although posaconazole exerts its primary effects on 
14-α-demethylase, a CYP450-dependent enzyme, it does 
not appear to undergo extensive oxidative metabolism via 
hepatic CYP450 enzymes.7,20 Following administration of a 
radiolabeled dose of posaconazole in normal volunteers, it 
was reported that 77% and 14% cumulative radioactivity was 
recovered in the feces and urine, respectively. Approximately 
66% of the excreted drug in the feces was the parent 
compound. In the plasma, the majority of radioactivity was 
associated with unchanged posaconazole. A glucuronide con-
jugate of posaconazole was the primary metabolite detected. 
These findings are in stark contrast with the metabolic profile 
of other triazole antifungals, such as voriconazole, which 
undergo a much greater degree of hepatic metabolism.
elimination
The total body clearance of posaconazole is approximately 
16 L/hour.20 Renal clearance of posaconazole is negligible at 
0.684 mL/hour, accounting for ,0.001% of the administered 
dose.20 Approximately 77% of the administered dose of 
posaconazole is recovered unchanged in the feces.20 Human 
and animal data strongly suggest that fecal excretion is the 
primary route of elimination of posaconazole.20 The half-life 
of posaconazole is approximately 25–31 hours in healthy 
adults.13 Comparatively, the half-life of posaconazole was 
found to be similar among groups of patients with normal 
renal function and those with renal disease. including those 
undergoing hemodialysis.21 No trend regarding degree of 
hepatic impairment and total posaconazole exposure has 
been noted.22
In vitro activity
Posaconazole exhibits excellent in vitro activity against 
  various fungi, including Candida spp, Cryptococcus 
neoformans, Aspergillus spp, Mucor spp, Rhizopus 
spp, Blastomyces spp, Coccidioides spp, Histoplasma spp, 
Paracoccidioides spp, Penicillium spp, Sporothrix spp, 
Trichophyton spp, and Pseudallescheria spp (Table 1).23–38 
It has been reported that posaconazole retains activity 
against some fluconazole- and itraconazole-resistant fungi.32 
Although posaconazole minimum inhibitory concentrations 
(MICs) for these azole-resistant isolates typically remained 
below 1 µg/mL, it should be noted that a positive correlation 
is typically observed between posaconazole MICs and 
MICs to fluconazole.32,39 A notable exception to this trend 
is Candida krusei.32 Of a sample of 114 isolates of C. krusei 
with decreased susceptibility to fluconazole, 113 remained 
susceptible to posaconazole.32
Although posaconazole exhibits a broad spectrum of 
activity against moulds, some species, such as Aspergillus cali-
doustus, Fusarium oxysporum, and Scedosporium prolificans 
exhibit intrinsic in vitro resistance to posaconazole.38,40,41 
Additionally, acquired resistance to posaconazole has 
emerged among previously susceptible pathogens, such 
as Aspergillus fumigatus, during the course of therapy.42 
Commonly, posaconazole resistance in such isolates has 
been attributed to mutations in the CYP51A gene that alter 
the affinity of azoles for their target enzyme, lanosterol-14 
α-demethylase.42,43 It should be noted that, among isolates 
of A. fumigatus exhibiting mutations in the CYP51A gene, at 
least 18 different amino acid alterations have been   noted.43 
As a result, variable-resistance phenotypes have been Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 1 in vitro activity of posaconazole and select antifungal agents against various yeasts and moulds23,32,35,38,40,41,72
Drug/organism MIC50 (µg/mL) MIC90 (µg/mL) Range (µg/mL) Reference
Candida albicans (n = 2359) 32
  Fluconazole 
  Posaconazole 
  voriconazole
0.25 
0.03 
0.007
0.5 
0.03 
0.015
0.12–.128 
0.007–.8 
0.007–. 8
Candida glabrata (n = 607) 32
  Fluconazole 
  Posaconazole 
  voriconazole
8 
1 
0.25
32 
2 
1
0.5–.128 
0.007–.8 
0.015–8
Candida parapsilosis (n = 439)  32
  Fluconazole 
  Posaconazole 
  voriconazole
1 
0.12 
0.015
4 
0.25 
0.12
0.12–128 
0.015–1 
0.007–8
Candida tropicalis (n = 319) 32
  Fluconazole 
  Posaconazole 
  voriconazole
1 
0.06 
0.06
2 
0.25 
0.12
0.12–.128 
0.015–.8 
0.007−.8
Candida krusei (n = 114) 32
  Fluconazole 
  Posaconazole 
  voriconazole
32 
0.5 
0.25
64 
1 
0.5
8–128 
0.12–2 
0.12–2
Candida lusitaniae (n = 42) 32
  Fluconazole 
  Posaconazole 
  voriconazole
0.5 
0.03 
0.007
4 
0.12 
0.06
0.12–64 
0.015–1 
0.007–0.5
Cryptococcus neoformans (n = 373) 33
  Fluconazole 
  itraconazole 
  Posaconazole
8 
0.25 
0.12
16 
0.5 
0.5
0.25–.128 
0.03–1 
0.015–1
Aspergillus fumigatus (n = 553) 40
  itraconazole 
  Posaconazole 
  voriconazole
0.5 
0.25 
0.25
1 
0.5 
0.5
0.12–2 
0.03–2 
0.06–4
Aspergillus flavus (n = 76) 40
  itraconazole 
  Posaconazole 
  voriconazole
0.5 
0.25 
0.5
1 
0.5 
1
0.12–2 
0.06–2 
0.06–1
Aspergillus niger (n = 59) 40
  itraconazole 
  Posaconazole 
  voriconazole
2 
0.25 
0.5
.8 
1 
1
0.5–.8 
0.12–2 
0.12–2
Aspergillus terreus (n = 35) 40
  itraconazole 
  Posaconazole 
  voriconazole
0.5 
0.25 
0.25
0.5 
0.25 
0.5
0.12–1 
0.06–0.5 
0.06–1
Aspergillus versicolor (n = 24) 40
  itraconazole 
  Posaconazole 
  voriconazole
1 
0.5 
0.25
2 
1 
1
0.12–.8 
0.006–2 
0.03–2
Aspergillus calidoustus (n = 4) 40
  itraconazole 
  Posaconazole 
  voriconazole
2 
2 
2
NA 
NA 
NA
0.122 
0.25–8 
0.25–4
Rhizopus spp (n = 101) 23
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole 
  Caspofungin
0.25 
0.5 
0.25 
8 
.16
0.5 
4 
1 
.8 
.16
0.03–0.5 
0.03–.8 
0.06–4 
2–.8 
.16
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observed. In one collection of 34 itraconazole-resistant   
A. fumigatus, 74% were cross-resistant to posaconazole and 
65% were cross-resistant to voriconazole.43 Furthermore, it 
was noted that the position and type of amino acid substitu-
tion within the CYP51A protein determined the pattern of 
azole cross-resistance expressed. For instance, itraconazole-
resistant isolates with alterations at codons 98, 138, 431, and 
434 exhibited cross-resistance to posaconazole and voricon-
azole, whereas isolates with substitutions at codons 54 and 
216 remained susceptible to voriconazole.43
Table 1 (Continued)
Drug/organism MIC50 (µg/mL) MIC90 (µg/mL) Range (µg/mL) Reference
Mucor spp (n = 41) 23
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole 
  Caspofungin
0.25 
0.5 
0.5 
.8 
.16
0.5 
.8 
2 
.8 
.16
0.125–4 
0.25–.8 
0.06–2 
4–.8 
.16
Fusarium spp (n = 67) 35
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
8 
16 
16 
16
32 
32 
32 
32
Fusarium solani (n = 39) 35
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
16 
– 
32 
16
32 
– 
32 
32
Fusarium verticillioides (n = 31) 38
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
1 
0.5 
0.5 
2
2 
2 
0.5 
2
1–2 
0.5–$16 
0.25–1 
1–4
Fusarium proliferatum (n = 10) 38
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
1 
$16 
2 
4
2 
$16 
$16 
8
1–4 
$16 
1–$16 
1–8
Fusarium oxysporum (n = 9) 38
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
2 
$16 
2 
4
4 
$16 
4 
8
1–4 
$16 
2–4 
2–8
Scedosporium prolificans (n = 55) 41
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
.16 
.32 
.8 
4
.16 
.32 
.8 
4
2–.16 
.32 
.8 
1–8
Scedosporium apiospermum (n = 13)
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
4 
0.5 
1 
0.25
16 
4 
2 
0.5
1–16 
0.25–8 
0.25–2 
0.03–0.5
41
Pseudallescheria boydii complex (n = 84) 72
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
16 
2 
1 
0.5
.16 
.16 
2 
1
2–.16 
0.5–.16 
0.12–.16 
0.12–.16
Pseudallescheria boydii (n = 30) 72
  Amphotericin B 
  itraconazole 
  Posaconazole 
  voriconazole
.16 
1 
0.5 
0.5
.16 
.16 
1 
1
2–.16 
0.5–.16 
0.12–1 
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Dovepress 
Dovepress
304
Zoller et al
Clinical trials
Prophylaxis
The effectiveness of oral posaconazole 200 mg three times 
daily versus oral fluconazole 400 mg daily or itraconazole 
200 mg twice daily was compared as prophylaxis against 
invasive fungal infections in patients with neutropenia 
secondary to chemotherapy for acute myelogenous leukemia 
or myelodysplastic syndrome.44 In total, 304 patients were 
assigned to the posaconazole treatment group, 240 to 
fluconazole, and 58 to itraconazole. Patients were studied 
until they fulfilled one of the endpoints, ie, remission from 
neutropenia, occurrence of invasive fungal infection, or a total 
of 12 weeks of prophylaxis. Among the patients who were 
reported to have either a proven or probable invasive fungal 
infection, seven (2%) occurred in the posaconazole group, 
25 (8%) occurred in the fluconazole or itraconazole group 
(95% confidence interval [CI] −9.7, −2.5; P , 0.001). Fewer 
patients, ie, two (1%), were also found to experience an inva-
sive aspergillosis infection in the posaconazole group versus 
20 (7%) in the fluconazole or itraconazole groups (95% CI 
−9.1, −3.1; P , 0.001). The authors also noted a lengthen-
ing in survival time among posaconazole-treated subjects 
(P = 0.04). It is important to note that this was not a double-
blinded trial. Although the evaluators were blinded, those 
making treatment decisions were not and therefore may have 
been biased. Additionally, the finding that fewer proven or 
probable Aspergillus infections occurred in the posaconazole 
group is not surprising because the majority of patients in the 
comparator group received fluconazole. Unfortunately, not 
much information was provided regarding those who failed 
therapy. Although samples were collected for determination 
of drug levels, these were not correlated with outcome nor 
was it mentioned if they were used to correct doses for those 
who may have had subtherapeutic drug levels.
In another study, patients who developed graft-versus-host 
disease following allogeneic hematopoietic stem cell trans-
plantation were given either posaconazole or fluconazole as 
prophylaxis against invasive fungal infection.45 Patients were 
randomized to receive either posaconazole 200 mg three times 
daily (n = 301) or fluconazole 400 mg once daily (n = 299) 
for a fixed 112-day treatment period. At the end of the study 
period, the authors reported that the incidence of all invasive 
fungal infections was similar between the groups, ie, posa-
conazole 5.3% and fluconazole 9.0% (P = 0.07). However, 
posaconazole was found to be superior in preventing probable 
or proven aspergillosis. Only 2.3% of patients treated with 
posaconazole were diagnosed with aspergillosis, compared 
with 7% of patients in the fluconazole group (P = 0.006). 
Although overall mortality was similar between the two treat-
ment groups, death secondary to invasive fungal infection 
was significantly lower among posaconazole-treated subjects 
(1% versus 4% in the fluconazole group; P = 0.046). However, 
it should be noted that criteria for determining cause of death 
were not provided. Therefore, it is difficult to assess how death 
secondary to invasive fungal infection was confirmed. This 
trial was powered under the assumption that 93 patients would 
experience an invasive fungal infection. In reality, because 
only 43 cases of invasive fungal infection were noted, only 
conclusions based on noninferiority can be drawn. Lastly, 
although the investigators did measure posaconazole plasma 
concentrations, no correlation was provided between drug 
levels and efficacy.
Treatment
The safety and efficacy of posaconazole were analyzed in 
an open-label trial with patients having fungal infection 
of the central nervous system that were refractory to or 
intolerant to standard therapy.46 Patients were administered 
800 mg daily of posaconazole suspension in divided doses 
(200 mg four times daily or 400 mg twice daily) for up to 
one year. Doses were administered with food or a nutritional 
supplement. Plasma posaconazole concentrations were 
not measured. A total of 39 patients were included in the 
final analysis. The most common pathogen isolated was C. 
neoformans (n = 29). Of the 29 patients with cryptococcal 
disease, 26 had refractory disease that had not responded 
to a reasonable trial of standard therapy. The remaining 10 
patients had infections caused by a variety of fungal patho-
gens, including   Aspergillus spp (n = 4), Pseudallescheria 
boydii (n = 2), Coccidioides immitis, H. capsulatum, Ram-
ichloridium mackenziei,   Apophysomyces elegans plus a 
Basidiomycetes spp. Fourteen of the 29 patients (48%) with 
cryptococcal meningitis were noted to have successful out-
comes, comprising four complete responses and 10 partial 
responses. These rates of response are similar to those noted 
following salvage therapy with amphotericin B lipid com-
plex and better than those reported with voriconazole.47,48 Of 
the 15 patients who experienced an unsuccessful outcome, 
eight were deemed to be treatment failures, six had stable 
disease, and one was undetermined. It should be noted that 
the definition for response used in this trial was based solely 
on resolution of symptoms and radiographic findings, and did 
not include criteria regarding absence or presence of positive 
cultures. Among the 10 patients with central nervous system 
infection due to other fungal species, five responded (two 
complete and three partial) to posaconazole therapy. Four of Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
305
Posaconazole for invasive fungal infections
the patients who did not respond to therapy died within two 
weeks following posaconazole salvage therapy.
The efficacy of posaconazole salvage therapy in a case 
series of eight patients with chronic granulomatous disease 
and invasive mould infections was reported.49 All patients 
had received voriconazole prior to enrollment in the study. 
A causative pathogen was identified in six of the eight subjects. 
The identified pathogens included Aspergillus spp (n = 2), 
Phaeoacremonium parasiticum (n = 2), Scedosporium apio-
spermum (n = 1), and Paecilomyces variotti (n = 1). All patients 
had infection that involved the lungs. Seven patients received 
posaconazole 400 mg solution twice daily and one patient 
received 200 mg three times daily. The mean duration of 
therapy was 10 months. Monitoring of plasma posaconazole 
concentrations was not reported. Seven of the eight patients 
demonstrated a complete response to therapy. One patient with 
persistent P . variotti failed treatment. Long-term therapy with 
posaconazole was well tolerated, with gastrointestinal symp-
toms being the most commonly reported adverse event.
A post hoc analysis evaluated the safety and efficacy 
of posaconazole as salvage therapy for invasive fungal 
infections in patients following solid organ transplantation.50 
Investigators evaluated 23 patients who had developed proven 
or probable invasive fungal infection and were refractory 
or intolerant to standard antifungal treatments. Patients 
received posaconazole suspension at a dose of 800 mg daily 
(200 mg four times daily or 400 mg twice daily) for a mean 
of 119 days. Complete or partial response to therapy was 
noted for 13 of 23 (57%) of patients. Response according to 
specific pathogen was seven of 12 patients with aspergillosis, 
two of two with fusariosis, one of one with cryptococcosis, 
and one of two with zygomycosis. Interestingly, the three 
patients infected with Candida spp did not respond to posa-
conazole therapy. One patient was infected with Candida 
glabrata (posaconazole MIC = 0.125 µg/mL) and C. krusei 
(MIC not determined), one with C. glabrata (posaconazole 
MIC .8 µg/mL), and one with Candida parapsilosis (MIC 
not determined). Plasma posaconazole concentrations were 
not reported for these three patients. Adverse effects of posa-
conazole were seen in 12 of the 23 patients, most of which 
were gastrointestinal events, including mild to moderate 
nausea and vomiting. Despite only being available as an 
oral formulation, posaconazole demonstrated good activity 
as salvage therapy among patients infected with problematic 
fungal pathogens. However, the lack of response noted with 
the three Candida spp is concerning, and suggests the pos-
sibility of emergence of secondary resistance to posaconazole 
following exposure to other azoles.
Another post hoc subanalysis was conducted to determine 
the safety and efficacy of posaconazole in patients with 
invasive fungal infections and renal impairment.51 The analy-
sis included 65 patients from a Phase III trial who had renal 
impairment, defined as creatinine clearance ,50 mL/min 
or a serum creatinine level .2 mg/dL, and a control group 
of 173 patients with acceptable renal function. Patients 
had either probable or proven refractory invasive fungal 
infections or were intolerant to standard antifungal therapy. 
Patients were administered posaconazole suspension 
800 mg daily (200 mg four times daily while hospitalized 
or 400 mg twice daily while outpatients) with food. The 
most commonly encountered pathogen in both groups was 
Aspergillus, accounting for 63% and 38% of infections in 
the renally impaired and acceptable renal function groups, 
respectively. No differences between groups were noted 
with respect to response (approximately 50%) or tolerabil-
ity. Adverse events occurred in 49% of patients with renal 
impairment and in 42% of patients in the control group, with 
the most common event being nausea. These data suggest 
that posaconazole is safe and effective in patients with renal 
impairment. These findings are important owing to concerns 
about using azoles that contain cyclodextrin in patients with 
impaired renal function.
Posaconazole has been evaluated in patients with HIV for 
the treatment of oropharyngeal candidiasis and/or esophageal 
candidiasis refractory to treatment with either fluconazole or 
itraconazole.52 Patients received posaconazole dosed at either 
400 mg twice daily for three days then 400 mg once daily for 
25 days or 400 mg twice daily for 28 days. Of the 176 patients 
in the modified intent-to-treat population, 132 patients (75%) 
were considered to have responded clinically to treatment. 
Mycologic response assessed at week 4 in 126 patients 
was 36.5%. Rates of clinical response were similar among 
patients with fluconazole-resistant (73%) and itraconazole-
resistant (74%) isolates. The response rates were similar 
between the two regimens, being 75.3% for the once-daily 
regimen and 74.7% for the twice-daily regimen. However, 
of the 132 patients who responded initially, a follow-up 
assessment performed four weeks after treatment completion 
revealed relapse of infection in 32 of the 40 patients who had 
taken the once-daily regimen (80%) and 27 of 40 patients 
who had taken the twice-daily regimen (68%). Because it is 
unlikely that posaconazole will be routinely used in azole-naïve 
patients with oropharyngeal and/or esophageal candidiasis, 
the fact that this study enrolled patients with fluconazole- 
and itraconazole-resistant Candida is significant. Therefore, 
this study was able to demonstrate that posaconazole may be Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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clinically useful against Candida nonresponsive to and/or 
having reduced susceptibility to fluconazole and itraconazole. 
Although both posaconazole regimens tested did appear to be 
efficacious, determination of plasma concentrations and infor-
mation regarding concurrent food ingestion were not reported. 
This information would be useful for the determination of an 
optimal dosing strategy in these indications.
In a head-to-head comparison, patients with HIV 
and oropharyngeal candidiasis were treated with either 
posaconazole or fluconazole.53 Findings from this study 
revealed that 200 mg of posaconazole on day 1 followed 
by 100 mg daily was noninferior to 200 mg of fluconazole 
on day 1 followed by 100 mg daily. Both medications were 
administered with food. After 14 days of treatment, clinical 
success in the modified intent-to-treat group was seen in 
155 of 169 (91.7%) patients receiving posaconazole and in 
148 of 160 (92.5%) patients receiving fluconazole (95% CI 
−6.61%, 5.04%). Additionally, patients received follow-up 
on day 42 to determine the rate of relapse. Again, both regi-
mens demonstrated similar rates of clinical relapse, ie, 31.5% 
for posaconazole and 38.2% for fluconazole (P = 0.24). 
However, assessment of mycologic success after 42 days, 
defined as a yeast culture showing #20 cfu/mL of Candida 
spp, revealed that 40.6% of patients receiving posaconazole 
and 26.4% of patients receiving fluconazole had mycologic 
success (P = 0.038). Although both drugs produce a suc-
cessful initial outcome, posaconazole was more effective at 
sustaining a mycologic response after the medication was 
discontinued. Although this study used clinical and micro-
biologic endpoints for efficacy evaluation, clinical outcomes 
may be more relevant from a patient perspective. Because 
few patients with HIV and candidiasis achieve and maintain 
fungal eradication, symptom resolution may provide the best 
marker of success.
The efficacy of posaconazole as salvage therapy has 
been examined in patients with probable or proven invasive 
aspergillosis and a hematologic malignancy.54 Fifty-three 
patients were treated with posaconazole 200 mg four 
times daily while in the hospital and 400 mg twice whilst 
outpatients. All patients took their doses with either a 
nutritional supplement or fatty meal. Response rates were 
compared with contemporary controls treated with either 
high-dose ($7.5 mg/kg/day) lipid amphotericin B (n = 52) 
or caspofungin (70 mg on day 1 followed by 50–100 mg 
daily) in combination with a high-dose lipid formulation 
of amphotericin B (n = 38). Of the 53 patients treated with 
posaconazole, 40% demonstrated a response compared with 
8% of patients treated with amphotericin B and 11% treated 
with the combination therapy (P , 0.01). Additionally, 
Aspergillus-related mortality was significantly lower among 
posaconazole-treated patients at 40% compared with controls 
at 65%–68% (P # 0.02). According to a multivariate analysis, 
posaconazole therapy was independently associated with an 
improved response compared with high-dose lipid amphot-
ericin B (odds ratio [OR] 9.5; 95% CI, 2.8, 32.5; P , 0.001) 
and the combination regimen (OR 4.0; 95% CI, 1.1, 14.5; 
P = 0.03). Additionally, during 12 weeks of follow-up, posa-
conazole was associated with an overall higher survival rate 
compared with the other groups (P # 0.04). However, it is 
important to note that 77.8% of the patients treated with high-
dose lipid amphotericin B and the combination of high-dose 
lipid amphotericin B plus caspofungin had received a regular 
dose (3–5 mg/kg/day) lipid formulation of amphotericin B as 
their primary therapy. This caveat is underscored by recent 
findings that failed to demonstrate an improvement in patient 
outcomes among those treated for invasive aspergillosis 
with liposomal amphotericin B at doses of 3 mg/kg/day and 
10 mg/kg/day.55 However, the data do provide evidence that 
a change in therapy, rather than a dosage increase, should 
be made if a patient does not respond to primary treatment. 
Similar findings were noted in an open-label study of patients 
with invasive aspergillosis refractory to at least seven days 
of antifungal therapy or intolerant to conventional   therapy.56 
In this trial, outcomes from 107 patients who received 
posaconazole 800 mg daily (200 mg four times daily while 
hospitalized and 400 mg twice daily while outpatients) with 
food or a nutritional supplement for up to 372 days (median 
of 56 days) were compared with those in 86 historic controls. 
Patients were enrolled and received posaconazole if they 
had a confirmed diagnosis of invasive aspergillosis, and 
were included in the analysis if they took at least one dose 
of posaconazole. Control subjects were selected if they had 
proven or probable invasive aspergillosis and had at least 
one response assessment during salvage therapy. Control 
subjects were excluded if they died with 72 hours of initiation 
of salvage therapy or were receiving mechanical ventilation 
at baseline. Plasma samples were obtained from patients 
treated with posaconazole and used for drug concentra-
tion determination. Response rates in posaconazole-treated 
patients were 42% versus 26% for control patients (95% CI, 
1.50, 11.04; P = 0.006). Response rates in patients treated 
with posaconazole who had pulmonary and nonpulmonary 
aspergillosis were 39% and 53%, respectively. According to 
an analysis of plasma concentration versus outcome, it was 
noted that higher posaconazole concentrations were asso-
ciated with improved response rates. Patients undergoing Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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salvage therapy represent a highly diverse patient population. 
Although the investigators made good attempts at controlling 
for population differences, it is important to recognize this 
variability exists when comparisons are made with historic 
controls. In this study, one variable that stands out is the fact 
that 57% of the controls were treated before 1999, whereas 
81% of the posaconazole-treated patients were enrolled in 
2000–2001. Another limitation of this study is the lack of 
information regarding baseline severity of illness. Because 
patients treated with posaconazole had to be treated with an 
oral formulation, one might argue that clinicians may have 
been less likely to allow their more severely ill patients to 
take part in the study.
Posaconazole has also been demonstrated to be   efficacious 
in patients with chronic refractory coccidioidomycosis.57 
Fifteen patients were identified with coccidioidomycosis 
who had been treated with a variety of therapies, including 
amphotericin B. Patients were treated with posaconazole 
suspension 400 mg twice daily (some patients received 
200 mg four times daily while hospitalized) as continuous 
therapy for 34 to 365 days. Response to therapy was seen 
in 11 of the 15 participants (73%), and four were complete 
responders. In recipients who responded, an improvement 
was normally seen between one and six months of treatment. 
Similar findings were reported in a case series of six patients 
with refractory coccidioidomycosis.58 Patients in this series 
received posaconazole 800 mg daily (200 mg four times 
daily or 400 mg twice daily) in divided doses for 1–2 years. 
At the end of the study period, five of the six recipients had 
successful outcomes.
The efficacy of posaconazole was demonstrated for histo-
plasmosis in a case series of patients who were intolerant or 
refractory to standard treatment.59 Six patients were treated 
with posaconazole 800 mg/day in divided doses for up to 34 
weeks. All recipients had successful clinical outcomes, with 
improvements seen within the first month of therapy.
The efficacy of posaconazole for the treatment of 
probable or proven invasive fusariosis was examined in a 
retrospective analysis of 21 patients who were intolerant or 
refractory to other therapies.60 All patients were treated with 
posaconazole 800 mg (200 mg four times daily or 400 mg 
twice daily) administered with food. Ten of the 21 patients 
(48%) had a complete or partial response to therapy. Among 
patients with leukemia who received posaconazole for more 
than three days, the response rate was 50%. It should be noted 
that, unlike several previous studies, subjects in this study 
were not classified as having a successful outcome if their dis-
ease remained stable. Response was higher for patients with 
leukemia who recovered from myelosuppression   compared 
with those who remained neutropenic (67% versus 20%). 
Of the six patients with a history of hematopoietic stem cell 
transplantation, only one patient responded to treatment. 
Although these results are encouraging, the severity of ill-
ness of patients at baseline was not provided. However, it did 
appear that posaconazole was the least effective among the 
sickest patients, ie, persistently neutropenic patients with 
leukemia, and patients (20%) who underwent hematopoietic 
stem cell transplantation (17%). Unfortunately, the infecting 
Fusarium spp were not reported. This information is vital 
for extrapolation to a broader population, because several 
Fusarium spp, such as F . solani, exhibit in vitro resistance 
to posaconazole (Table 1).
Posaconazole has also been examined for the treatment 
of zygomycosis.61 In a retrospective study, 91 patients with 
proven (n = 22) or probable (n = 69) zygomycosis who were 
intolerant or refractory to other antifungals and subsequently 
treated with posaconazole 800 mg daily (200 mg four times 
daily or 400 mg twice daily) were evaluated. All posacon-
azole doses were administered with food or a nutritional 
supplement. After 12 weeks of treatment, 60% of patients had 
a complete or partial response and 21% had stable disease. 
It was noted that success rates were similar regardless of 
predisposing conditions or sites of infection. Owing to the 
relatively small number of Zygomycetes species, determi-
nation of statistical differences in outcome with respect to 
infecting species was not feasible. However, observed rates 
of success did vary from 28.6% with Rhizomucor spp (n = 7) 
to 100% with Absidia spp (n = 2). For the two species having 
the largest number of isolates, the response rates were 52% 
for patients infected with Rhizopus spp (n = 25) and 76.5% 
with Mucor spp (n = 17). Although 64 of the 91 patients in 
this series underwent surgical debridement, success rates 
were similar for patients who did (61%) and did not (62%) 
undergo this procedure. A major limitation of this study was 
the fact that clinicians from many diverse centers were asked 
to complete questionnaires about their patients subsequent 
to treatment. Therefore, differences in institutional practices 
and recall bias limit the strength of the data. Despite these 
limitations, the data do provide a glimpse into the use of 
posaconazole for Zygomycoses.
Adverse events and tolerability
The most common adverse events for posaconazole, as 
listed in the package insert, are increased hepatic enzymes, 
hepatocellular damage, bilirubinemia, nausea, and vomiting.7 
A summary of the adverse events noted with posaconazole, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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fluconazole, and itraconazole are presented in Table 2. Some 
patients in the clinical trials received posaconazole up to 
1600 mg/day.7 No difference was seen in adverse events 
between patients receiving the high dosages and those 
receiving lower dosages. In addition, there is one reported 
accidental overdose in a patient who consumed 1200 mg 
twice daily for three days, with no adverse events seen.
The long-term safety of posaconazole was examined via 
comparison of 109 patients who received posaconazole for 
six months or longer and 319 patients receiving posacon-
azole for less than six months.62 Among patients receiving 
posaconazole for six months or more, slightly more anorexia, 
increased serum glutamic pyruvic transaminase levels, head-
aches, and menstrual disorders were observed. However, 
the authors stated that they could not find any trend in these 
events that suggested an increased risk of adverse effects with 
longer treatment. They also noted that no trends of adverse 
effects on laboratory values or increased risk of cardiac 
events were seen with longer exposure to the medication.
Drug interactions
Posaconazole is metabolized by uridine diphosphate 
glucuronidation and is a substrate for p-glycoprotein efflux. 
Therefore, inducers and inhibitors of these paths, such as 
  efavirenz, may affect the plasma concentrations of posacon-
azole.7 Some medications that may decrease the bioavailability 
of posaconazole because of their effect on gastric pH or motil-
ity include cimetidine, esomeprazole, and metoclopramide.10 
Posaconazole is an inhibitor of CYP3A4 and may increase 
levels of medications metabolized through this pathway. 
As a result, medications such as midazolam, ritonavir, and 
atazanavir, and the calcineurin inhibitors, cyclosporine and 
tacrolimus, require frequent monitoring when coadministered 
with posaconazole.7,50,51 For the same reason, the coadmin-
istration of posaconazole and sirolimus is contraindicated. 
When administered concurrently, a significant interaction 
is noted between posaconazole and rifabutin.63 This interac-
tion results in a 43% (P = 0.005) decrease in peak plasma 
concentration (Cmax) and a 49% (P = 0.008) decrease in the 
AUC of posaconazole.   Coadministration also produced an 
increase of 31% (P = 0.016) in Cmax and a 72% (P , 0.001) 
increase in AUC of rifabutin, probably due to inhibition of 
CYP3A4. Therefore, the concomitant use of rifabutin and 
posaconazole should generally be avoided, owing to the risk 
of breakthrough fungal infections secondary to reduced posa-
conazole exposure and the increased risk for adverse effects 
from rifabutin, such as uveitis and leukopenia. Posaconazole 
may also increase concentrations of vinca alkaloids, digoxin, 
HMG-CoA reductase inhibitors metabolized by CYP3A4, and 
calcium channel blockers metabolized by CYP3A4.7
Coadministration of posaconazole and phenytoin resulted 
in a 44% (P = 0.012) decrease in Cmax and a 52% (P = 0.007) 
decrease in the AUC of posaconazole.64 Although phenytoin 
levels were not significantly elevated, there was inconsistency 
between patients, and coadministration could affect phenytoin 
levels. Therefore, phenytoin levels should be monitored while 
the drugs are being concurrently administered. The mecha-
nism for this interaction may be due to the induction of uridine 
diphosphate glucuronosyltransferase activity by phenytoin. 
Because coadministration can decrease posaconazole levels, 
the concomitant use of phenytoin and posaconazole should 
be avoided unless the benefit outweighs the risk.
A review of drug–drug interactions with systemic triazole 
antifungals describes medications that are contraindicated for 
use with posaconazole.65 Astemizole, halofantrine, bepridil, 
sertindole, cisapride, quinidine, pimozide, and terfenadine 
are contraindicated due to a potential for QT interval pro-
longation and risk of torsades de pointes. Ergot alkaloids are 
contraindicated for use with posaconazole because the latter 
may increase the patient’s exposure to the ergot alkaloid, 
causing ergotism.7
Therapeutic drug monitoring
Owing to the high inter- and intrapatient variability associ-
ated with plasma posaconazole concentrations, some clini-
cians have advocated the use of therapeutic drug monitoring 
to ensure that adequate drug levels are achieved. Although 
several authors have documented variability in plasma posa-
conazole concentrations, few data have been published that 
specifically correlate drug levels with clinical efficacy.66 One 
retrospective study evaluated the clinical efficacy of posa-
conazole among 54 patients who had plasma concentrations 
determined during therapy.67 These authors defined a low 
plasma concentration of posaconazole as being ,500 ng/mL. 
Accordingly, it was reported that 44% of patients receiving 
a prophylactic regimen of 200 mg three times daily and 22% 
of patients administered a curative regimen of 400 mg twice 
Table  2  Adverse  events  of  posaconazole  compared  with 
fluconazole/itraconazole7
Posaconazole Fluconazole/ 
itraconazole
Overall adverse events 34% 34%
Nausea 7% 8%
vomiting 5% 7%
Bilirubinemia 2% 3%
increased hepatic enzymes 2% 1%Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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daily experienced low posaconazole plasma concentrations. 
Among the 36 patients who received posaconazole prophy-
laxis, only two developed a possible invasive fungal infec-
tion. Both of these patients were noted to have low plasma 
posaconazole concentrations. Of the 18 patients treated 
curatively with posaconazole, two patients with low plasma 
posaconazole concentrations had a complete response, one 
died from an unrelated cause, and one exhibited stable disease. 
In a prospective trial examining the efficacy of salvage therapy 
with posaconazole for the treatment of invasive aspergillosis, 
plasma concentrations of posaconazole were assessed and 
related to outcome.56 In this study, it was observed that patients 
in the highest concentration quartile, with a mean plasma 
concentration of 1250 ng/mL, exhibited the best response 
rate at 75%. Conversely, those in the lowest concentration 
quartile, with a mean plasma concentration 134 ng/mL, 
exhibited the lowest response rate at 24%. Because there was 
considerable variability with respect to interpatient plasma 
posaconazole concentrations, the authors were not able to 
recommend a definitive target concentration. Rather, the 
suggestion was made that, whenever possible, efforts should 
be made to optimize posaconazole absorption (ie, take dose 
with food or a nutritional supplement).
Acknowledging the tremendous variability associated 
with the bioavailability of posaconazole and the potential 
for poor outcomes secondary to suboptimal exposure, it may 
be recommended that plasma posaconazole concentrations 
be evaluated to ensure that adequate absorption occurs. 
Currently, it is recommended that plasma posaconazole 
concentrations .700 ng/mL be targeted.68,69 Additional 
studies are needed to determine if this is the optimal target 
concentration for efficacy.
Patient-focused perspectives
To determine the cost-effectiveness of posaconazole versus 
other azoles for the prevention of invasive fungal infections, 
an analysis was conducted in high-risk neutropenic patients 
with acute myeloid leukemia and myelodysplastic syn-
drome.70 The total cost for posaconazole treatment and 
prophylaxis was less than the costs associated with flu-
conazole and itraconazole. With respect to quality of life, 
prophylaxis with posaconazole resulted in a gain of 0.08 
quality-adjusted life years in comparison with prophylaxis 
using other azoles. Another study has also examined the cost-
effectiveness of posaconazole prophylaxis against invasive 
fungal infection.71 According to this report, treatment with 
posaconazole resulted in fewer invasive fungal infections per 
patient compared with fluconazole or itraconazole therapy 
(0.05 versus 0.11). Based on their model, they determined 
that posaconazole is very likely to be cost-effective compared 
with fluconazole or itraconazole in preventing invasive fun-
gal infections in neutropenic patients. Using an economic 
model, they also found that use of posaconazole provides 
an additional 0.08 undiscounted life-years per patient over 
fluconazole or itraconazole. The authors also noted that, even 
though the cost of prophylaxis was higher in the posaconazole 
group, costs associated with treating invasive fungal infec-
tions were lower. The authors estimated that posaconazole 
prophylaxis resulted in a savings of approximately $600 per 
patient in discounted medical costs.
Conclusion
Posaconazole is a broad-spectrum azole antifungal that 
has demonstrated clinical efficacy against a variety of 
  difficult-to-treat fungal infections. The activity of posa-
conazole against various moulds is particularly exciting. 
However, saturable absorption and lack of an intravenous 
formulation may limit the utility of posaconazole in some 
patient populations, especially those who are severely ill. 
Furthermore, clinicians will need to be vigilant for break-
through infections, which may be caused by problematic 
pathogens resistant to or outside the spectrum of activity of 
posaconazole.
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